JK07
As of the edition of 20 October 2026, JK07 is a drug known only by a code name: stopped in 2026; acts on ERBB3 and ERBB4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Code name only
- Registered trials
- 1, 1 stopped early
- Disease areas
- Heart and blood vessels; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Salubris Biotherapeutics | Lead sponsor of trials | 2025 to now |